Limits...
Circulating stem cell vary with NYHA stage in heart failure patients.

Fortini C, Toffoletto B, Fucili A, Puppato E, Olivares A, Beltrami AP, Fiorelli V, Bergamin N, Cesselli D, Morelli C, Francolini G, Ferrari R, Beltrami CA - J. Cell. Mol. Med. (2011)

Bottom Line: Level of CD45(-) CD34(-) CD90(+) CXCR4(+) cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively).Both the entity and kinetic of this process varied in distinct cell subsets.Specifically, differently from HSCs and EPCs/CECs, MSCs and TCSCs significantly increased with the progression of the disease, suggesting a possible distinct role of these cells in the pathophysiology of HF.

View Article: PubMed Central - PubMed

Affiliation: University of Ferrara and Cardiovascular Research Center, Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy. cfortini@mtagroup.net

Show MeSH

Related in: MedlinePlus

Circulating haematopoietic stem cells in HF patients. Level of CD90+ and CD105+ HSC (A and B, respectively) are analysed in peripheral blood of controls and patient. No significative difference are observed between healthy donors and patients considered for New York Association class. In the CXCR4+ subtype, only the subset CD45+CD34+ CD90+CXCR4+ differs significatively between controls and patients in NYHA class III (C). No differences are reported in CD45+CD34+CD105+CXCR4+ cells (D). Regarding PDGFR-positive cells, statistically significative increase is observed in CD45+CD34+ class (E), but not in CXCR4+ component (F). Significative difference between controls and patients are reported as P value. Data are expressed as mean ± S.D.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4373363&req=5

fig03: Circulating haematopoietic stem cells in HF patients. Level of CD90+ and CD105+ HSC (A and B, respectively) are analysed in peripheral blood of controls and patient. No significative difference are observed between healthy donors and patients considered for New York Association class. In the CXCR4+ subtype, only the subset CD45+CD34+ CD90+CXCR4+ differs significatively between controls and patients in NYHA class III (C). No differences are reported in CD45+CD34+CD105+CXCR4+ cells (D). Regarding PDGFR-positive cells, statistically significative increase is observed in CD45+CD34+ class (E), but not in CXCR4+ component (F). Significative difference between controls and patients are reported as P value. Data are expressed as mean ± S.D.

Mentions: Conversely, HSCs (Fig. 3), although significantly augmented in patients with respect to controls, did not show a significant trend to increase with NYHA class. Emblematically, the fraction characterized as CD45+CD34+CD90+ expressing the CXCR4 receptor (Fig. 3C), peaks in class III patients and returns to control level in class IV. CD45+CD34+CD105+ cells expressing the CXCR4 and CD45+CD34+ cells expressing PDGFR were also increased in patients (Fig. 3D and E).


Circulating stem cell vary with NYHA stage in heart failure patients.

Fortini C, Toffoletto B, Fucili A, Puppato E, Olivares A, Beltrami AP, Fiorelli V, Bergamin N, Cesselli D, Morelli C, Francolini G, Ferrari R, Beltrami CA - J. Cell. Mol. Med. (2011)

Circulating haematopoietic stem cells in HF patients. Level of CD90+ and CD105+ HSC (A and B, respectively) are analysed in peripheral blood of controls and patient. No significative difference are observed between healthy donors and patients considered for New York Association class. In the CXCR4+ subtype, only the subset CD45+CD34+ CD90+CXCR4+ differs significatively between controls and patients in NYHA class III (C). No differences are reported in CD45+CD34+CD105+CXCR4+ cells (D). Regarding PDGFR-positive cells, statistically significative increase is observed in CD45+CD34+ class (E), but not in CXCR4+ component (F). Significative difference between controls and patients are reported as P value. Data are expressed as mean ± S.D.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4373363&req=5

fig03: Circulating haematopoietic stem cells in HF patients. Level of CD90+ and CD105+ HSC (A and B, respectively) are analysed in peripheral blood of controls and patient. No significative difference are observed between healthy donors and patients considered for New York Association class. In the CXCR4+ subtype, only the subset CD45+CD34+ CD90+CXCR4+ differs significatively between controls and patients in NYHA class III (C). No differences are reported in CD45+CD34+CD105+CXCR4+ cells (D). Regarding PDGFR-positive cells, statistically significative increase is observed in CD45+CD34+ class (E), but not in CXCR4+ component (F). Significative difference between controls and patients are reported as P value. Data are expressed as mean ± S.D.
Mentions: Conversely, HSCs (Fig. 3), although significantly augmented in patients with respect to controls, did not show a significant trend to increase with NYHA class. Emblematically, the fraction characterized as CD45+CD34+CD90+ expressing the CXCR4 receptor (Fig. 3C), peaks in class III patients and returns to control level in class IV. CD45+CD34+CD105+ cells expressing the CXCR4 and CD45+CD34+ cells expressing PDGFR were also increased in patients (Fig. 3D and E).

Bottom Line: Level of CD45(-) CD34(-) CD90(+) CXCR4(+) cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively).Both the entity and kinetic of this process varied in distinct cell subsets.Specifically, differently from HSCs and EPCs/CECs, MSCs and TCSCs significantly increased with the progression of the disease, suggesting a possible distinct role of these cells in the pathophysiology of HF.

View Article: PubMed Central - PubMed

Affiliation: University of Ferrara and Cardiovascular Research Center, Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy. cfortini@mtagroup.net

Show MeSH
Related in: MedlinePlus